TTF2 and neoplasm: The NanoString tumor panel (Table S3-4) detected in treatment-naïve tumors of the L-TTF2 group higher immune infiltration (e.g., cytotoxic T-cells, B-cells) and checkpoint markers (e.g., PDCD1, CTLA4, TIGIT; Fig. 1I, Fig. S2F).